Inherited retinal diseases: Linking genes, disease-causing variants, and relevant therapeutic modalities.
CRISPR-Cas
DNA editing
Disease-causing variant
Gene
Gene therapy
Genotype-phenotype correlation
Inherited retinal diseases
RNA editing
Retinal degeneration
Retinitis pigmentosa
Translational read-through
Journal
Progress in retinal and eye research
ISSN: 1873-1635
Titre abrégé: Prog Retin Eye Res
Pays: England
ID NLM: 9431859
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
received:
19
07
2021
revised:
11
11
2021
accepted:
16
11
2021
pubmed:
29
11
2021
medline:
14
7
2022
entrez:
28
11
2021
Statut:
ppublish
Résumé
Inherited retinal diseases (IRDs) are a clinically complex and heterogenous group of visual impairment phenotypes caused by pathogenic variants in at least 277 nuclear and mitochondrial genes, affecting different retinal regions, and depleting the vision of affected individuals. Genes that cause IRDs when mutated are unique by possessing differing genotype-phenotype correlations, varying inheritance patterns, hypomorphic alleles, and modifier genes thus complicating genetic interpretation. Next-generation sequencing has greatly advanced the identification of novel IRD-related genes and pathogenic variants in the last decade. For this review, we performed an in-depth literature search which allowed for compilation of the Global Retinal Inherited Disease (GRID) dataset containing 4,798 discrete variants and 17,299 alleles published in 31 papers, showing a wide range of frequencies and complexities among the 194 genes reported in GRID, with 65% of pathogenic variants being unique to a single individual. A better understanding of IRD-related gene distribution, gene complexity, and variant types allow for improved genetic testing and therapies. Current genetic therapeutic methods are also quite diverse and rely on variant identification, and range from whole gene replacement to single nucleotide editing at the DNA or RNA levels. IRDs and their suitable therapies thus require a range of effective disease modelling in human cells, granting insight into disease mechanisms and testing of possible treatments. This review summarizes genetic and therapeutic modalities of IRDs, provides new analyses of IRD-related genes (GRID and complexity scores), and provides information to match genetic-based therapies such as gene-specific and variant-specific therapies to the appropriate individuals.
Identifiants
pubmed: 34839010
pii: S1350-9462(21)00090-2
doi: 10.1016/j.preteyeres.2021.101029
pii:
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
101029Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.